The long-term outcome of treated sensitized patients who undergo heart transplantation

Clinical Transplantation

Volumn 25, Issue 1, 2011, Pages

  Kobashigawa, Jon A ^a   Patel, Jignesh K ^a   Kittleson, Michelle M ^a   Kawano, Matt A ^a   Kiyosaki, Krista K ^a   Davis, Stephanie N ^a   Moriguchi, Jaime D ^a   Reed, Elaine F ^b   Ardehali, Abbas A ^c  

^a Cedars Sinai Hospital   (United States)

^b Department of Pathology ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Circulating antibodies; Heart transplant; Outcome; Sensitization; Treatment

Indexed keywords

IMMUNOGLOBULIN; PANEL REACTIVE ANTIBODY; RITUXIMAB; THYMOCYTE ANTIBODY;

ARTICLE; BLOOD GROUP TYPING; CARDIAC ALLOGRAFT VASCULOPATHY; CONTROLLED STUDY; DESENSITIZATION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; PLASMAPHERESIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SENSITIZATION; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; BLOOD GROUPING AND CROSSMATCHING; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; PLASMAPHERESIS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79551697003     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01334.x     Document Type: Article

References (17)

1. Itescu S, Tung TC, Burke EM et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998: 98: 786.
2. Kobashigawa JA, Sabad A, Drinkwater D et al. Pretransplant panel reactive antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 1996: 94: II294.
3. Suciu-Foca N, Reed E, Marboe C et al. The role of anti-HLA antibodies in heart transplantation. Transplantation 1991: 51: 716.
4. McCarthy JF, Cook DJ, Smedira NG et al. Vascular rejection in cardiac transplantation. Transplant Proc 1999: 31: 160.
5. Michaels PJ, Epejo ML, Kobashigawa J et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003: 22: 58.
6. Nwakanma LU, Williams JA, Weiss ES et al. Influence of pretransplant panel-reactive antibody on outcomes in 8.160 heart transplant recipients in recent era. Ann Thorac Surg 2007: 84: 1556.
7. Reed EF, Demetris AJ, Hammond E et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006: 25: 153.
8. Danskine AJ, Smith JD, Stanford RE, Newell H, Rose ML. Correlation of anti-vimentin antibodies with acute and chronic rejection following cardiac transplantation. Hum Immunol 2002: 63: S30.
9. Suarez-Alvarez B, Lopez Vazquez A, Gonzalez MZ et al. The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant 2007: 7: 1842.
10. Lawson C, Holder AL, Stanford RE, Smith J, Rose ML. Anti-intercellular molecule-1 antibodies in sera of heart transplant recipients: a role in endothelial cell activation. Transplantation 2005: 80: 264.
11. Pisani BA, Mullen GM, Malinowska K et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999: 18: 701.
12. Holt DB, Lublin DM, Phelan DL et al. Mortality and Morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. J Heart Lung Transplant 2007: 26: 876.
13. Balfour IC, Fiore A, Graff RJ, Knutsen AP. Use of rituximab to decrease panel-reactive antibodies. J Heart Lung Transplant 2005: 24: 628.
14. Itescu S, Burke E, Lietz K et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 2002: 105: 1214.
15. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998: 66: 507.
16. Rose ML, Danskine A, Smith JD et al. Mycophenolate mofetil (MMF) depresses antibody production after cardiac transplantation. Scientific Sessions 2000, New Orleans, Louisiana, November 12-15, 2000. Circulation 2000: 102: II.
17. Tambur AR, Pamboukian SV, Costanzo M et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 2005: 80: 1019.